Navigation Links
Leading DHA Expert and Former NIH Researcher, Dr. Norman Salem, Jr., to Join Martek as Chief Scientific Officer
Date:1/31/2008

COLUMBIA, Md., Jan. 31 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation (Nasdaq: MATK), a DHA omega-3 market leader, announced today that leading DHA researcher and expert Dr. Norman Salem, Jr., will be joining Martek Biosciences on February 4, 2008, as vice president and chief scientific officer.

Dr. Salem is one of the world's leading researchers on DHA and the functions of polyunsaturated fatty acids and lipids. He comes to Martek after 30 years with The National Institutes of Health where he led the internationally recognized Laboratory of Membrane Biochemistry and Biophysics. His latest scientific work focused on the role of DHA in neural development as well as how DHA is made in the body and incorporated into the brain and other organs.

As Martek's chief scientific officer, Dr. Salem will be responsible for leading clinical research, discovery, microbial biotechnology, and analytical sciences and will support the efforts of scientific affairs and medical research.

Dr. Salem received his B.S. degree in physics from Miami University and his Ph.D. in neurobiology from the University Of Rochester School Of Medicine. During his career, Dr. Salem has published over 200 research articles and book chapters. He was the 2002 recipient of the Supelco/Nicholas Pelick Research Award from the American Oil Chemists Society, which recognizes outstanding original research in fats, oils, lipid chemistry, or biochemistry. He currently serves as a research professor in the Department of Pediatrics at the F. Edward Hebert School of Medicine of Uniformed Services University of the Health Sciences.

"We are pleased to welcome Dr. Salem, a prominent expert on the science of DHA, to Martek. His scientific knowledge and experience in DHA research will provide Martek with important senior-level leadership for our clinical, scientific and research areas," said Steve Dubin, CEO of Martek Biosciences.

Martek Biosciences Corporation (Nasdaq: MATK) is a leader in the innovation and development of DHA omega-3 products that promote health and wellness through every stage of life. The company produces life'sDHA(TM), a sustainable and vegetarian source of the omega-3 fatty acid DHA (docosahexaenoic acid), for use in foods, beverages, infant formula, and supplements. The company also produces life'sARA(TM) (arachidonic acid), an omega-6 fatty acid, from a sustainable, vegetarian source, for use in infant formula. For more information on Martek Biosciences Corporation, visit http://www.martek.com. For a complete listing of life'sDHA products, visit http://www.lifesdha.com.

Sections of this release contain forward-looking statements. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's Form 10-K for the fiscal year ended October 31, 2007 and other filed reports on Form 10-K, Form 10-K/A, Form 10-Q and Form 8-K.

Contact:

Cassie France-Kelly

Consumer and Trade Media

Martek Biosciences

(443) 542-2116

media@martek.com

Kyle Stults

Investor Relations

Martek Biosciences

(410) 740-0081

investors@martek.com


'/>"/>
SOURCE Martek Biosciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
2. Thermo Fisher Scientific Acquires Leading Chromatography Consumables Provider, La-Pha-Pack
3. Masada Teams With Leading Waste Management Firm to Produce Ethanol From Municipal Solid Waste in the Dominican Republic
4. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
5. Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies
6. Germany Hosts World Leading Medical Industry Fair
7. VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease
8. Sureshield Coatings Company Established to Market Industry-Leading Portfolio of Advanced Coatings for Metal Surfaces
9. Leading Edge Research Underway in Fall Prevention for Seniors
10. Cognizant to Acquire marketRx, a Leading Provider of Life Sciences Market Analytics
11. 2007 Massachusetts Biotechnology Council MASS Opportunities Investment Conference Showcases Leading Growth Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , ... February 24, 2017 , ... ... procedures can be safely completed in an ambulatory surgery center (ASC) with satisfactory ... procedures and previous two-year TDR studies. , Jake Lubinski, president of AxioMed, ...
(Date:2/24/2017)... , Feb. 24, 2017  Aethlon Medical, Inc. ... note authored by its Chairman and CEO, Jim ... the Munich Security Conference last Saturday, Bill Gates ... could kill more people than nuclear weapons. Mr. Gates ... and U.K. intelligence agencies, that scientific terrorists have access ...
(Date:2/24/2017)... , ... February 24, 2017 , ... FireflySci, Inc is ... in late 2014, FireflySci had the goal of bringing their powerful cuvette ... to shape the path that FireflySci is going on as they add yet another ...
(Date:2/23/2017)... and NEW YORK , Feb. ... Lumeon , a leading digital health company, and ... provider of telemedicine and remote patient monitoring, announce ... telemedicine reimbursements.  DN Telehealth maximizes ... in real-time, extending consultations beyond a physical clinical ...
Breaking Biology Technology:
(Date:2/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... at the LEERINK Partners 6th Annual Global Healthcare Conference ... February 15, 2017 at 10 a.m. Eastern Time. ... be accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will ... Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/3/2017)... 2017  Texas Biomedical Research Institute announced that its Board ... as the Institute,s new President and CEO. Dr. Schlesinger ... 2017. He is currently the Chair of the Department of ... Microbial Interface Biology at Ohio State University. "We ... and CEO of Texas Biomed," said Dr. James O. ...
(Date:2/2/2017)... 2017  EyeLock LLC, a market leader of iris-based ... " What You Should Know About Biometrics in the ... authenticity is a growing concern. In traditional schemes, cryptography ... traditional authentication schemes such as username/password suffer from inherent ... offers an elegant solution to the problem of high-security ...
Breaking Biology News(10 mins):